Sources and selection criteria
We searched Medline and Google, using the terms "gene therapy" and "viral vectors." We also studied the websites www.wiley.co.uk/genmed/clinical and www. advisorybodies.doh.gov.uk/genetics/gtac for information on ongoing trials using viral vectors in the United Kingdom.
Viral gene therapy: successes and failures
In April 2002 the BBC online news service in the United Kingdom carried an emotive headline: "Bubble boy saved by gene therapy."
1 The 18 month old infant featured had a rare immune disorder, X linked severe combined immunodeficiency (X-SCID), caused by a defective gene on the X chromosome. This gene encodes the common C chain, an essential component of five cytokine receptors, all of which are necessary for the development of T cells and natural killer cells. Without the C chain, mature T cells and natural killer cells are completely absent, whereas B cells are usually present in normal or increased numbers. X-SCID is fatal during the first year of life because of severe recurrent infections. As a result, much of the child's short life is spent in a sterile plastic bubble, a barrier to potentially life threatening infectious organisms. A collaboration of scientists from London, Paris, and Milan used a retroviral vector to introduce a functional copy of the defective gene into bone marrow stem cells taken from the patient in the hope that after re-infusion they would engraft and reconstitute a normal immune system. 2 3 Integration and expression of the C transgene and development of the lymphocyte subgroups and their functions were analysed over a period of up to 2.5 years after gene transfer. No immediate adverse effects resulted from the procedure. The numbers and repertoire of T cells and their in vitro proliferative response to several antigens were nearly normal after two years. The therapy was hailed as a success and an important breakthrough for gene therapy as it pioneered an ex vivo procedure that avoided direct in vivo transfer of the vector.
However, within a year, two of the 10 children treated in France for X-SCID had developed a leukaemia-like disease. 4 Genetic analysis of the malignant cells showed that the retroviral vector, used to carry a functional copy of the defective C chain gene into the bone marrow stem cells, had inserted into the patients' DNA and activated an oncogene, LIM-only2 (LMO2), which is associated with childhood leukaemia. Although this insertional activation was not the only cause of the malignancy, it was considered to be one of the events that triggered it. However, it is important to note that these leukaemias associated with the gene therapy are so far clinically manageable. trial using an adenoassociated virus (AAV) expressing the gene for blood coagulation factor IX (FIX): recombinant AAV vectors are considered to be one of the safest for use in gene therapy as the virus does not cause disease in humans naturally and rarely integrates randomly into the genome. One patient on the trial had a 50% reduction in the need to administer factor IX and a second an 80% reduction. 5 However, in June 2003 Kay et al published a study conducted on mice, which found that the vector used in these trials integrates itself into regions of DNA containing genes more often than into non-coding regions. 6 The integration sites were distributed on the mouse genome, with no particular bias to one particular chromosome. However, it was clear that integration was occurring in active genes. This showed that the AAV vector could possibly cause similar cellular defects to those that led to cancer in the SCID patients.
Summary points
In addition to retroviral and AAV vectors, problems have also been encountered with adenoviral vectors. The death of a young man in the United States, Jesse Gelsinger, was attributed to the toxic effects of an adenoviral vector used to treat ornithine transcarbamylase (OTC) deficiency. 
Current status of viral gene therapy in the United Kingdom
Despite these recent reports, the field of gene therapy has come a very long way over the past decade. Gene transfer efficiencies have improved, and many new vectors are in preclinical studies. Viral vectors remain the gene transfer vehicles of choice for clinical trials in the United Kingdom and worldwide. 
Adenoviral vectors
Adenoviruses remain the most popular viral vectors in clinical trials because of their ability to transduce a broad range of dividing and non-dividing cells. In addition they replicate episomally and do not insert their genome into that of the host cell, which ensures less disruption of vital cellular genes. However, adenoviral vectors remain the most immunogenic of all the viral vectors currently in use. In the Gelsinger case, death was directly attributable to a massive inflammatory response to the first generation adenoviral vector. Scientists have therefore done their utmost to solve these problems and remove all non-essential viral genes to create a third generation of "gutless" vectors. However, studies in the rat brain have shown that an immune response can still be elicited by the adenoviral capsid proteins. The extent to which the vector elicits an immune response is linked to the dose of vector administered: the urgent challenge is to establish the dose at which the vector should be administered. However, assessing the amount of vector to deliver is made difficult by the variability of the immune response in humans. This was shown in the Gelsinger case. Jesse Gelsinger received the highest dose of vector in the trial (3.8×10 13 viral particles), whereas another patient received a similar dose (3.6×10 13 viral particles) but showed no side effects. As a result of the events in the United States, the UK Gene Therapy Advisory Committee assembled an adenoviral working committee, which made several recommendations including that the immune status and cytokine profile of the patients enrolled on the trial should be monitored before and after administration of the vector, to try to assess the patients' reaction to the treatment. Another recommendation was that the research community work towards a standardised method of assessing viral titre to ensure consistency through all clinical trials. 8 
Retroviral vectors
Retroviral vectors are being used in a range of clinical trials across the United Kingdom. One of the advantages of using retroviruses is their ability to integrate into the genome and maintain expression for long periods of time. However, given recent reports, the risk of oncogenesis induced by retroviral integration is clearly higher than thought previously. These risks must therefore be reduced by strategies such as targeting integration to inactive regions of the host genome. 8 One approach could be to use the site specific integration machinery of bacteriophage C31, which has recently been used in non-viral delivery approaches to achieve targeted integration in mouse and human cells. 
Replication competent viral vectors
The use of non-replicating viral vectors can severely limit the number of cells that are targeted. As a result, replication competent viral vectors have been developed that allow the delivery of genes to a small number of cells and their subsequent transfer to surrounding cells as the infection spreads. These are proving particularly effective for treating cancer in preclinical models. The adenoviral vector, ONYX-015, is deleted in the E1B region that binds to and inactivates p53. Under normal viral replication an adenovirus binds to and inactivates p53 to ensure efficient replication. Therefore, in theory, ONYX-015 is unable to replicate in normal cells, but in cancer cells, in which p53 is deleted, the virus is able to replicate and cause cell lysis. 10 However, this issue is not as clear as originally thought since the virus has been shown to replicate in p53 wild type cells. This approach is currently being tested in the United Kingdom to treat cancers of the head and neck, and liver. However, studies have indicated its limitations and areas where improvement is needed. For example, problems include a low transduction of tumour cells because of their low expression of the Coxsackie adenovirus receptor (CAR) required for adenoviral entry. New versions of ONYX-015 are being designed that remove the need to infect all tumour cells to gain complete remission. They have been engineered to deliver prodrug converting enzymes to tumour cells. The replication competent oncolytic herpes simplex virus (HSV) is also a popular vector currently in use in several clinical trials of cancer gene therapy in the United Kingdom. HSV1 is a large, double stranded DNA virus encoding at least 89 proteins. It has a wide cell tropism and remains extrachromosomal, therefore minimising the risk of insertional mutagenesis. Many of the replication competent viruses under investigation have had the ICP34.5 gene deleted and are predisposed to replicate in cancer cells but not in adjacent normal tissues. Viral replication leads to cell lysis, which releases a second wave of the virus that can infect adjacent tumour cells. These vectors show promise, and no adverse side effects have been reported to date.
Future prospects for viral gene therapy
Despite the X-SCID and Gelsinger cases no serious adverse events have so far been reported in gene therapy trials in the United Kingdom. This is at least in part due to the small numbers of patients treated. It is important that lessons are learnt from these cases and that they are used to improve our understanding of vector biology and pharmacology. Although GTAC has a central role in controlling gene therapy studies in the United Kingdom, calls have materialised for a harmonisation of legislation among European states and between Europe and the United States. 11 Clearly, more efforts are needed to improve vectors to prevent the risk of insertional mutagenesis and also to direct the expression of therapeutic genes to specific tissues using both transcriptional and transductional targeting. This, in turn, will reduce vector doses and potentially immunogenicity.
Despite the setbacks successes have been achieved. Of the 18 SCID patients treated for their life threatening condition, 17 are still alive and have had a healthy, functioning immune system for up to five years and a good quality of life. In addition to monogenic conditions, gene therapy also represents a viable treatment for multigenic disorders, such as cancer, either as a standalone treatment or in combination with chemotherapy or radiotherapy. A huge amount of work is yet to be done, but with efficient monitoring of trials and continuous improvements of viral vectors, gene therapy may still represent an important addition to the treatment armamentarium for a range of diseases.
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